Jump to content

Atransferrinemia

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Justjennifer (talk | contribs) at 03:30, 5 April 2011 (Disambiguated: microcyticmicrocytic anemia using Dab solver). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Atransferrinemia

Atransferrinemia, also called familial hypotransferrinemia,[1] is an autosomal recessive[2] metabolic disorder in which there is an absence of transferrin, a plasma protein that transports iron through the blood.

Atransferrinemia is characterized by anemia and hemosiderosis in the heart and liver. The iron damage to the heart can lead to heart failure. The anemia is typically microcytic and hypochromic (the red blood cells are abnormally small and pale). Atransferrinemia is extremely rare, with only eight cases documented worldwide.[3]

Symptoms

Severe microcytic hypochromic anemia, growth retardation and recurrent infections are the first clinical signs of the disease. Iron overload occurs mainly in the liver, heart, pancreas, thyroid, kidney and bone joints, leading to mild to severe symptoms of liver and heart failure, arthropathy and hypothyroidism. Death may occur due to heart failure or pneumonia. [citation needed]

Genetics

Atransferrinemia has an autosomal recessive pattern of inheritance, meaning both copies of the gene in each cell are defective.

A case study was done in 1961 on a 7-year-old girl who died of heart failure with atransferrinemia. The half-normal levels of transferrin in her parents' bloodstream supported the notion that this disorder is transferred in an autosomal recessive pattern.[4] Atransferrinemia was reported in only eight patients in six families as of the year 2000. A lack of scientific data and public outreach, however, have suggested that there is a higher number of current cases. Researchers used the first known case reported in the United States[5] and identified mutations in the TF gene as a probable cause of the disorder.

Treatment

Treatment with infusions of plasma or purified apotransferrin may stabilise or correct the anemia and growth defects.

References

  1. ^ Online Mendelian Inheritance in Man (OMIM): 209300
  2. ^ Hamill, Rl; Woods, Jc; Cook, Ba (1991). "Congenital atransferrinemia. A case report and review of the literature". American journal of clinical pathology. 96 (2): 215–8. ISSN 0002-9173. PMID 1862777. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Aslan, D; Crain, K; Beutler, E (2007). "A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene". Acta haematologica. 118 (4): 244–7. doi:10.1159/000112726. PMID 18097132.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Heilmeyer, L; Keller, W; Vivell, O; Keiderling, W; Betke, K; Woehler, F; Schultze, He (1961). "Congenital atransferrinemia in a 7-year-old girl" (Free full text). Deutsche medizinische Wochenschrift (1946) (in German). 86: 1745–51. doi:10.1055/s-0028-1113001. ISSN 0012-0472. PMID 13906010. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Beutler, E; Gelbart, T; Lee, P; Trevino, R; Fernandez, Ma; Fairbanks, Vf (15 December 2000). "Molecular characterization of a case of atransferrinemia" (Free full text). Blood. 96 (13): 4071–4. ISSN 0006-4971. PMID 11110675.{{cite journal}}: CS1 maint: multiple names: authors list (link)